ClinicalTrials.gov record
Completed Phase 1 Interventional

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT02342782

Public ClinicalTrials.gov record NCT02342782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen

Study identification

NCT ID
NCT02342782
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
City of Hope Medical Center
Other
Enrollment
20 participants

Conditions and interventions

Interventions

  • Autologous Hematopoietic Stem Cell Transplantation Procedure
  • Carmustine Drug
  • Cytarabine Drug
  • Etoposide Drug
  • Laboratory Biomarker Analysis Other
  • Melphalan Drug
  • Pharmacological Study Other
  • Yttrium Y 90 Basiliximab Biological

Procedure · Drug · Other + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 7, 2020
Primary completion
Sep 17, 2020
Completion
Nov 17, 2024
Last update posted
Mar 19, 2025

2020 – 2024

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02342782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02342782 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →